OBJECTIVE: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. STUDY DESIGN: The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175mg/m² on day 2, and IP paclitaxel 60mg/m² on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. RESULTS: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7%) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p=0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. CONCLUSIONS: Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.
OBJECTIVE: To reduce toxicities in cisplatin-based intraperitoneal (IP) chemotherapy, we substituted carboplatin for cisplatin. The purpose of this study was to provide preliminary toxicity data of carboplatin-based IP chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. STUDY DESIGN: The toxicity data of 19 primary ovarian cancerpatients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175mg/m² on day 2, and IP paclitaxel 60mg/m² on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period. RESULTS: The toxicity data in a total of 118 cycles were analyzed. Grade 3 or 4 leukopenia, neutropenia, and pain were more common in the IP group than the IV group. There were seven catheter-related complications. Fourteen patients (73.7%) were able to complete six cycles or more of IP chemotherapy. Survival results in the IP group were compared with those from the IV group; a prolonged progression-free survival was observed (26.6 vs. 20.7 months; p=0.038). Compared to the previous results with cisplatin-based IP chemotherapy, there was no significant difference in hematologic events. However, gastrointestinal, neurologic, and metabolic events in this study were definitely lower compared to those of cisplatin-based IP chemotherapy. CONCLUSIONS:Carboplatin-based IP and IV combination chemotherapy is feasible in patients with ovarian carcinoma after primary debulking surgery.
Authors: Setsuko K Chambers; H-H Sherry Chow; Mike F Janicek; Janiel M Cragun; Kenneth D Hatch; Haiyan Cui; Cynthia Laughren; Mary C Clouser; Janice L Cohen; Heather M Wright; Nisreen Abu Shahin; David S Alberts Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Angela Casado-Adam; Lidia Rodriguez-Ortiz; Sebastian Rufian-Peña; Cristobal Muñoz-Casares; Teresa Caro-Cuenca; Rosa Ortega-Salas; Maria Auxiliadora Fernandez-Peralbo; Maria Dolores Luque-de-Castro; Juan M Sanchez-Hidalgo; Cesar Hervas-Martinez; Antonio Romero-Ruiz; Javier Briceño; Álvaro Arjona-Sánchez Journal: J Clin Med Date: 2022-09-29 Impact factor: 4.964
Authors: Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Claus Wilki Fristrup; Per Pfeiffer; Michael Bau Mortensen Journal: Ther Adv Med Oncol Date: 2018-06-01 Impact factor: 8.168
Authors: Kyung Jin Eoh; Jung Yun Lee; Eun Ji Nam; Sunghoon Kim; Young Tae Kim; Sang Wun Kim Journal: J Korean Med Sci Date: 2017-12 Impact factor: 2.153